Are you planning for the end of the Brexit Transition Period?
Are you planning for the end of the Brexit Transition Period? 19th November 2020

Are you planning for the end of the Brexit Transition Period? (Nov 2020)

 

As the end of the Transition Period on 31st December 2020 draws ever closer, pharmaceutical companies are preparing for life outside the EU Single Market and Customs Union. Holding additional stock could provide a buffer against any potential border disruption that could occur during the transition to the controls that will be implemented on 1st January 2021.

 

 

Recent advice from the Department of Health and Social Care suggests that companies make stockpiling a key part of contingency planning. If you are planning to hold additional stock in line with this recommendation, we can offer MHRA regulated warehouse space for storing products in the UK available now. We can also provide fully temperature-controlled transportation for next day delivery that is aligned to GDP.

 

 

Other latest news
https://www.mawdsleys.co.uk/news/mawdsleys-are-now-the-distributor-of-manx-healthcare-contract-lines-in-england/ thumbnail image Mawdsleys is now the distributor of Manx Healthcare contract lines in England

Mawdsleys is delighted to be partnering with Manx Healthcare to distribute their contract products to hospitals in England.   Hospitals can view and check live stock levels and contract prices on Mawdsleys Online, and order in their normal way. For any queries hospitals can contact their Regional Hospital Account Manager or…

Read more
https://www.mawdsleys.co.uk/news/mawdsleys-and-oncoscience-launch-a-named-patient-program-for-cimaher-nimotuzumab-in-the-uk-and-ireland/ thumbnail image Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher®

Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingdom (UK) and Ireland to obtain access to CIMAher® (Nimotuzumab) on an unlicensed basis for the treatment of various types of cancer.   Nimotuzumab has been approved for marketing in 25 different countries worldwide for a variety of…

Read more